Stockreport

Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ -- Trulicity® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascu [Read more]